Subscribe to Life Science Success for cutting-edge insights, expert interviews, and a vibrant community. Your subscription fuels our mission and keeps you at the forefront of life sciences.
Chairman and Chief Executive Officer
As Chief Executive Officer for Arcellx, Rami Elghandour oversees a diverse and vibrant team that is reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. Under his leadership, the company completed an IPO and upsized public offering in 2022, and closed a transformational business development deal with Kite, a Gilead Company, in January 2023, worth up to $3.9 billion in future milestones. The partnership will support the co-development and co-commercialization of Arcellx’s lead product candidate, CART-ddBCMA, which is in a Phase 2 pivotal study and has potential to become a best-in-class CAR-T therapy for the treatment of relapsed/refractory multiple myeloma.
Prior to joining Arcellx, Elghandour served as President and Chief Executive Officer of Nevro. During his tenure, Nevro grew from a small private company to a public company approaching $400 million in revenue and a leader in neuromodulation. Previously, Elghandour was an investor with Johnson & Johnson Development Corporation (JJDC), where he led investments and served on the Board of Directors of several private companies.
A strong advocate of gender equity, diversity, and inclusion, Elghandour has earned recognition as an EY Entrepreneur of the Year, as one of the top CEOs in the U.S. and as one of the top CEOs for women and diversity. He is a recipient of the Bill Campbell award by Watermark for his influence, impact, and advocacy in promoting women and women’s issues.
Elghandour received an MBA from the Wharton School of Business at the University of Pennsylvania and holds a B.S. in Electrical and Computer Engineering from Rutgers University School of Engineering.